

AREN21.US18.CIP
Serial No. 09/995,225



Supplemental Information Disclosure Statement

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Ruoping Chen, et al.	Art Unit:	1646
		Examiner:	Nirmal Singh Basi
Serial No.:	09/995,225	Confirmation No.:	1454
Filed:	November 26, 2001	Docket No.:	AREN21.US18.CIP
For:	ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G PROTEIN-COUPLED RECEPTORS		
Customer No.:	35133		

MAIL STOP RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

VIA EXPRESS MAIL LABEL NO: EV552 953 743US
DATE SENT: June 21, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed. The Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☐ before the mailing date of a first Office Action on the merits.
- ☒ before the mailing date of a first Office Action upon the filing of a Request For Continued Examination under §1.114.

- ☐ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below);
- and**
- ☐ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☒ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Supplemental Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see “Statement” below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the Supplemental Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i)(1) (see “Statement,” “Petition,” and “Fees” below).
- ☒ Copies of references listed on the attached PTO Form SB/08A and PTO Form SB/08B, are enclosed herewith

EXCEPT THAT:

- ☐ In view of the voluminous nature of references @@@, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- ☐ Copies of references @@@ listed on the attached PTO Form SB/08A and PTO Form SB/08B, were previously cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. @@@, filed on @@@.

- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Pursuant to Fed. Reg. Vol. 69, No. 182, dated September 21, 2004, copies of U.S. Patents and U.S. Patent Publications need not be submitted as part of an Supplemental Information Disclosure Statement.

Statement under 37 C.F.R. § 1.97(e)

- ☐ The undersigned attorney hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

Statement under 37 C.F.R. § 1.704(d)

- ☐ The undersigned attorney hereby states that each item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than 30 days prior to the filing of the Supplemental Information Disclosure Statement.

Petition

- ☐ Applicant(s) hereby petitions the Assistant Commissioner to consider the references listed in this Supplemental Information Disclosure Statement, on the enclosed PTO Form SB/08A and PTO Form SB/08B, and the examination of the above-identified patent application.

Fees

- ☒ No Fee is owed by the applicant(s).
- ☐ The Supplemental Information Disclosure Statement Fee of \$_____ under 37 C.F.R. § 1.17(p) is authorized to be charged to Deposit Account No. 50-1275.
- ☐ The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.

Method of Payment of Fees

- ☐ Attached is a check in the amount of \$_____. This form is submitted in duplicate.


AREN21.US18.CIP
Serial No. 09/995,225

Supplemental Information Disclosure Statement

- ☐ Charge Deposit Account No. 50-1275 in the amount of \$_____. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☒ No fee or Statement is required under 37 C.F.R. § 1.97(b).

There are no listed references, which are not in the English language.


Respectfully submitted,



Michael A. Patané
Registration No. 42,982

Dated: June 21, 2006

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-6966 - Telephone
(215) 701-2100 - Facsimile



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/995,225		
		Filing Date	November 26, 2001		
		First Named Inventor	Ruoping Chen et al.		
		Art Unit	1646		
		Examiner Name	Nirmal Singh Basi		
Sheet	1	of	1	Attorney Docket Number	AREN21.US18.CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	MIYATA, M., ET AL., "Role of Thalamic Phospholipase C β 4 Mediated by Metabotropic Glutamate Receptor Type 1 in Inflammatory Pain," <i>The Journal of Neuroscience</i> , 23(22):8098-8108, (September 3, 2003)	
	AB	SALT, T.E. and EATON, S.A., "The Function of Metabotropic Excitatory Amino Acid Receptors in Synaptic Transmission in the Thalamus : Studies With Novel Phenylglycine Antagonists," <i>Neurochem. Int.</i> , 24(5):451-458, (1994)	
	AC	Abstract #328 from the February 2006 <i>Keystone Symposium</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.